MEDP stock news · Medpace Holdings, Inc.
Get alerts for MEDP
Follow Medpace Holdings, Inc. (MEDP) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MEDPMedpace will host a webinar about developing cell and gene therapies with its expert team.
NeutralMedpace announced an upcoming webinar about cell and gene therapy development. It may help sponsors, but reports no new business result, so it does not change the outlook for Medpace.
Barclays keeps its hold rating on Medpace Holdings and bumps up the target price to $675.
NeutralBarclays raised its share-price goal for Medpace but kept its Hold rating. The mixed analyst view does not change the company’s outlook.
UBS changes its price goal for Medpace to $700, up from $673.
NeutralUBS raised its price goal for Medpace but kept its Neutral rating. The note gives no new details about the company's business, so it does not change Medpace's prospects.
Medpace Hldgs shares what happened during their earnings call for the third quarter of 2026.
Good for MEDPMedpace's sales and profit grew, and quarterly study awards reached a record. Strong demand supports its outlook, despite cancellations and planned expansion costs.